Cat. No.: HY-N7526

Naphthazarin

(Synonyms: DHNQ; 5,8-Dihydroxy-1,4-naphthoquinone)

1 Cited Publications

Customer Review

Based on 1 publication(s) in Google Scholar

Naphthazarin (DHNQ) is a microtubule depolymerizing agent. Naphthazarin can improve motor function and reduce neuroinflammation in mouse models of Parkinson's disease. Naphthazarin can induce tumor cell apoptosis, autophagy, and cell cycle arrest. Naphthazarin can also induce erythrocyte apoptosis. Naphthazarin can be used in the research of tumors and neurodegenerative diseases.

For research use only. We do not sell to patients.

Purity: 99.59%
CAS No.: 475-38-7
Formula: C₁₀H₆O₄
Molecular Weight:190.15

Storage:

Powder -20°C, 3 years , 4°C, 2 years ; In solvent -80°C, 6 months , -20°C, 1 month

Naphthazarin Chemical Structure

CAS No.: 475-38-7

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Publications (1)
Solvent & Solubility
- In Vitro
- In Vivo
Purity & Documentation
References
Help & FAQs
Bioz

Biological Activity

Description

All PI3K Isoforms :

All Akt Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A2780	IC₅₀	0.08 μM Compound: 15	Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay Antiproliferative activity against human A2780 cells after 2 days by alamar-blue assay	[PMID: 19028102]
A-375	IC₅₀	8.85 μM Compound: SK-6	Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human A-375 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
BT-549	GI₅₀	0.43 μM Compound: 1	Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay Antiproliferative activity against human BT-549 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
CAL-51	GI₅₀	0.56 μM Compound: 1	Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay Antiproliferative activity against human CAL-51 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HaCaT	IC₅₀	0.7 μM Compound: 7e ; Naphthazarin	Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line) Antiproliferative (inhibition of cell growth) activity against HaCaT cells (human keratinocyte line)	[PMID: 9371243]
HCC1954	GI₅₀	0.49 μM Compound: 1	Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCC1954 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HCT-116	GI₅₀	0.16 μM Compound: 1	Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay Antiproliferative activity against human HCT-116 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
HCT-116	IC₅₀	1.04 μM Compound: SK-6	Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human HCT-116 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
HeLa	IC₅₀	9.37 μM Compound: 15	Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells Inhibition of histidine-tagged mouse MKP1 catalytic domain expressed in human Hela cells	[PMID: 19028102]
HepG2	IC₅₀	4.97 μM Compound: SK-6	Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay Antiproliferative activity against human HepG2 cells assessed as inhibition of cell proliferation measured after 3 days by MTT assay	[PMID: 39129245]
HL-60	IC₅₀	0.8 μM Compound: 2	Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 72 hrs by MTT assay	[PMID: 28987605]
HL-60	IC₅₀	0.93 μM Compound: 2	Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay Cytotoxicity in human HL60 cells assessed as reduction in cell viability incubated for 48 hrs by MTT assay	[PMID: 28987605]
K562	GI₅₀	1.7 μM Compound: 1	Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay Antiproliferative activity against human K562 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MCF7	GI₅₀	0.43 μM Compound: 1	Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MCF7 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MOLM-13	GI₅₀	0.28 μM Compound: 1	Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MOLM-13 cells measured after 72 hrs by SRB assay	[PMID: 35687347]
MV4-11	GI₅₀	0.19 μM Compound: 1	Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay Antiproliferative activity against human MV4-11 cells measured after 72 hrs by SRB assay	[PMID: 35687347]

In Vitro

Naphthazarin (0-10 μM; 24 h) can stimulate apoptosis in human red blood cells by increasing oxidative stress and surface ceramide abundance^[1].
Naphthazarin (0-80 μM; 24 h) can inhibit the cell viability, induce cell apoptosis, autophagy and cell cycle arrest, and suppress the PI3K/Akt pathway in A549 cells^[2].
Naphthazarin (10-1000 nM; 30 h) can alleviate MPP⁺-induced activation in primary cultured rat astrocytes^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Western Blot Analysis^[3]

Cell Line:

Primary cultured astrocyte treated MPP⁺
Concentration:

10 nM, 100 nM and 1 μM
Incubation Time:

Pretreated with 6 h, then co-incubation for 24 h
Result:

Inhibited the levels of GFAP.

In Vivo

Naphthazarin (0.1-1 mg/kg; intraperitoneal injection; 5 days) exerts a protective effect in a mouse model of Parkinson's disease^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Male C57BL/C mice aged 7-8 weeks old weighing approximately 20-23 g) treated MPTP (HY-W114750) to induce Parkinson's disease model^[3]
Dosage:

0.1 mg/kg and 1 mg/kg
Administration:

Intraperitoneal injection; 5 days
Result:

Improved the motor function of the mice at 1 mg/kg
Protected dopaminergic neurons and inhibited neuroinflammation in the mice at 0.1 mg/kg and 1 mg/kg.
Suppressed MPTP-induced glial activation at 0.1 mg/kg and 1 mg/kg.

Chemical Information

CAS No. 475-38-7
Appearance Solid
Molecular Weight 190.15
Formula C₁₀H₆O₄
Color Brown to black
SMILES

O=C1C=CC(C2=C1C(O)=CC=C2O)=O
Synonyms

DHNQ; 5,8-Dihydroxy-1,4-naphthoquinone
Structure Classification
- Quinones
- Naphthalene Quinones
- Phenols
- Polyphenols
Initial Source
Shipping

Room temperature in continental US; may vary elsewhere.

Storage

Powder	-20°C	3 years
	4°C	2 years
In solvent	-80°C	6 months
	-20°C	1 month

Publications (1)

All

Sort by:

Journal Impact Factor

Int J Biol Macromol

Identification of Vitamin K3 and its analogues as covalent inhibitors of SARS-CoV-2 3CLpro. [Abstract]

2021 Jul 31:183:182-192. PMID: 33901557

Solvent & Solubility

In Vitro:

DMSO : 10 mg/mL (52.59 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

5.2590 mL

26.2950 mL

52.5901 mL

5 mM

1.0518 mL

5.2590 mL

10.5180 mL

10 mM

0.5259 mL

2.6295 mL

5.2590 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

In Vivo:

Select the appropriate dissolution method based on your experimental animal and administration route.

Stock Solution Working Solution

For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for In Vivo experiments, it is recommended to prepare freshly and use it on the same day.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

Protocol 1

Add each solvent one by one: 10% DMSO 90% (20% SBE-β-CD in Saline)

Solubility: 0.71 mg/mL (3.73 mM); Suspended solution; Need ultrasonic

This protocol yields a suspended solution of 0.71 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (7.1 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

In Vivo Dissolution Calculator

Please enter the basic information of animal experiments:

Dosage Dosage
mg/kg
Animal Weight (Per Animal) Animal Weight (Per Animal)
g
Dosing Volume (Per Animal) Dosing Volume (Per Animal)
μL
Number of Animals Number of Animals

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.

Please enter your animal formula composition:

%
DMSO +

Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
%
+
+
%
Tween-80 + +
%
Saline +

The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).

Working solution concentration: 0.22 mg/mL

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (280 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Omar Aljanadi, et al. Stimulation of Suicidal Erythrocyte Death by Naphthazarin. Basic Clin Pharmacol Toxicol. 2015 Dec;117(6):369-74. [Content Brief]

[2]. Acharya BR, et al. The microtubule depolymerizing agent naphthazarin induces both apoptosis and autophagy in A549 lung cancer cells. Apoptosis. 2011 Sep;16(9):924-39. doi: 10.1007/s10495-011-0613-1 [Content Brief]

[3]. Seon Young Choi, et al. Naphthazarin has a protective effect on the 1-methyl-4-phenyl-1,2,3,4-tetrahydropyridine-induced Parkinson's disease model. J Neurosci Res. 2012 Sep;90(9):1842-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month. When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	5.2590 mL	26.2950 mL	52.5901 mL	131.4752 mL
	5 mM	1.0518 mL	5.2590 mL	10.5180 mL	26.2950 mL
	10 mM	0.5259 mL	2.6295 mL	5.2590 mL	13.1475 mL
	15 mM	0.3506 mL	1.7530 mL	3.5060 mL	8.7650 mL
	20 mM	0.2630 mL	1.3148 mL	2.6295 mL	6.5738 mL
	25 mM	0.2104 mL	1.0518 mL	2.1036 mL	5.2590 mL
	30 mM	0.1753 mL	0.8765 mL	1.7530 mL	4.3825 mL
	40 mM	0.1315 mL	0.6574 mL	1.3148 mL	3.2869 mL
	50 mM	0.1052 mL	0.5259 mL	1.0518 mL	2.6295 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

Naphthazarin

Apoptosis Compound Library

Immunology/Inflammation Compound Library

Kinase Inhibitor Library

PI3K/Akt/mTOR Compound Library

Stem Cell Signaling Compound Library

Natural Product Library

Anti-Cancer Compound Library

Autophagy Compound Library

Anti-Aging Compound Library

Differentiation Inducing Compound Library

Oxygen Sensing Compound Library

Phenols Library

Glycolysis Compound Library

Cytoskeleton Compound Library

Glutamine Metabolism Compound Library

Anti-Breast Cancer Compound Library

Anti-Lung Cancer Compound Library

Anti-Pancreatic Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Anti-Parkinson's Disease Compound Library

Neurodegenerative Disease-related Compound Library

Anti-Obesity Compound Library

Angiogenesis-Related Compound Library

Glucose Metabolism Compound Library

Anti-Liver Cancer Compound Library

Anti-Colorectal Cancer Compound Library

Anti-Cancer Natural Product Library

Plant-Sourced Natural Product Library

Human Metabolite Library

Anti-Prostate Cancer Compound Library

Anti-Pulmonary Fibrosis Compound Library

Cancer Stem Cells Compound Library

Pain-Related Compound Library

Membrane Protein-targeted Compound Library

Cell Death Library

Serine/Threonine Kinase Inhibitor Library

Anti-Hematopathy Compound Library

Anti-Ovarian Cancer Compound Library

Multi-Target Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Natural Product Library Plus

Natural Product and Natural Product-Like Compound Library

Bioactive Compound Library

Anti-Gastric Cancer Compound Library

Anti-Fibrosis Compound Library

Anti-Brain Cancer Compound Library

Protein Kinase Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

Cell Proliferation Compound Library

High-Throughput Bioactive Compound Library

High-Throughput Natural Product Library

Anti-Rheumatic Arthritis Compound Library

Mass Spectrometry Human Metabolite Library

Mongolian Medicine Compound Library

Quinones Library

Lactylation Compound Library

Mass Spectrometry Natural Product Library

Publications Citing Use of MedChemExpress (MCE) Naphthazarin

All PI3K Isoforms

All Akt Isoforms

Biological Activity

Chemical Information

Publications (1)

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

Naphthazarin Related Classifications

Cat. No.: HY-N7526